Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
A phase 3 trial of Futibatinib, Zimberelimab, Durvalumab, Pembrolizumab, Gemcitabine and Cisplatin in biliary tract cancer, run by Taiho Pharmaceutical Co., Ltd., now recruiting.
Overview
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer is a phase 3 interventional study registered as NCT07710885 by Taiho Pharmaceutical Co., Ltd., with 784 participants planned, started 2026-06-24 and due to reach its primary completion in 2030-04-30. Interventions recorded: Futibatinib, Zimberelimab, Durvalumab, Pembrolizumab, Gemcitabine and Cisplatin.
Similar pages
not linked directly; found by shared links- TrialPhase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Shares Araris Biotech (Taiho), Futibatinib, Cisplatin, Pembrolizumab and the tag pipeline.
- TrialAK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialCosiporfin Sodium for Injection Photodynamic Therapy
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Shares Araris Biotech (Taiho), Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialDurvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialStudy of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Shares Zimberelimab, Cisplatin, Pembrolizumab and the tag pipeline.
- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.